: iStockAnalyst.com Symbols Feed

Stocks On The Move: CSUH, GNBT, KERX

Mon, 12 Oct 2009 19:45:29 GMT

CSUH.ob: Shares of Celsius Holdings (CSUH) touched forty five cents during early trading on Monday after an Investment Nation interview with the company's CEO Steve Haley last Thursday highlighted some important developments for the company.[More...]

Mentor Capital Top Gainer in Cancer Immunotherapy Index

Fri, 28 Aug 2009 17:53:33 GMT

SAN DIEGO--(BUSINESS WIRE)--The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR - News).[More...]

SciGen Buys China Rights to Generex Oral Insulin Spray

Mon, 14 Apr 2008 17:33:55 GMT

SciGen, Ltd. (ASX: SIE), a Singapore company that trades in Australia, has licensed the China rights to Oral-lyn™,...[More...]

Fed Liquidity

Tue, 11 Mar 2008 13:50:15 GMT

Good morning. Premarket futures are positive after the Federal Reserve announced plans to lend up to $200 billion through a new lending tool. Along with the Fed's actions, some also cite the little known Anderson Forecast which predicted that the U.S. wou[More...]

Weekly Market Update - Still Waiting for an Up Week

Mon, 21 Jan 2008 02:28:15 GMT

The financials killed us again this week with Washington Mutual, Citigroup and Merrill Lynch announcing massive losses. This was accompanied by more gyrations among the bond insurers. Based on write-offs by Merrill and others, analysts figure most of ACA's guarantees for CDOs are close to worthless. Ambac and MBIA are flailing about in tatters with ratings agencies seemingly lowering their credit ratings every week.It was a standoff in tech with bellwether Intel coming in light on fourth quarter earnings and providing cautious forward guidance offset by IBM beating analyst expectations in both Q4 and 2008 projections. AMD surpised by meeting their projections for 4Q07 but still reported a large loss. They are by no means out of the woods yet.Despite generally positive results from GE, manufacturing took it on the chin when the Philadelphia Fed's reading on regional manufacturing activity came in stunningly below expections.&l[More...]

Weekly Market Update - data just OK, markets rally anyway

Sat, 08 Dec 2007 16:54:10 GMT

Market CommentsMarkets staged a strong rally on Thursday that accounted for most of the gains seen this week. Interestingly, part of the impetus for the rally was an employment report from ADP that most analysts felt was largely overstated. The other incentive for investors was the announcement of the rescue plan for sub-prime homeowners by President Bush and Treasury Secretary Paulson. I am not sure why this was such a strong catalyst for a rally when nothing that wasn't already known was presented. Markets took off anyway and we now have two weeks in a row where the major averages achieved gains.In other news that had an unexpected effect, OPEC held production steady and the US government reported a large draw-down in crude stocks. Instead of rallying, oil actually fell and finished the week down slightly.The anxiously awaited Labor Dept. payrolls number was an[More...]

Generex Biotech - can the stock add to recent gains?

Tue, 04 Dec 2007 14:14:24 GMT

Starting in November, Generex Biotechnology (GNBT) has been quite volatile. That's about the time the company announced that its Oral-Lyn product had been licensed for commercial use in India. In October, a similar license was obtained in South Africa. The company is in the process of securing approvals to market the product in various Middle Eastern countries, as well.In mid-November, Wall Street Strategies, an independent stock market research company, published a report on the company. They pointed out that the India news was a distinct positive for GNBT and that the stock is a buy. In addition, their analyst...[More...]

Weekly Market Update and TradeRadar portfolio round-up

Mon, 26 Nov 2007 07:30:25 GMT

The week started off poorly with a Goldman downgrade of Citigroup. Things went further downhill from there. Lowe's, Target and Freddie Mac added to negative tone. We got a little positive blip in October housing starts but the housing market remains far underwater. The Fed released the minutes from their last FOMC meeting and surprised investors by revealing the decision to lower rates was "close". They also provided an economic forecast for 2008 that predicted slower growth due to continued financial market turmoil.All in all, this week was pretty much like the last few weeks: volatile and in the end, depressing for investors.Against this backdrop, there has been a higher level of trading in the TradeRadar portfolio and the holdings have changed quite a bit. There were a number of disappointments delivered by TradeRadar stock picks, stops were hit and we have ended up with a more bearish set of investments. Let's look at what happened to[More...]

Weekly Market Update - Is this selloff serious?

Mon, 22 Oct 2007 15:46:27 GMT

Naturally the markets would have to tumble as I was traveling Friday. It always seems that major down moves occur when I am out of pocket. After reviewing the carnage this week...[More...]

Generex to Raise $12.25 Million in Registered Direct Offering

Tue, 15 Sep 2009 14:50:00 GMT

Generex Biotechnology, a developer of drug delivery systems and technologies, has received commitments from investors to purchase $12.25 million of securities in a registered direct offering.
Generex expects to receive net proceeds of approximately $11.66 after deducting placement agent fees and other offering expenses.
Generex has entered into securities purchase agreements with the investors pursuant to which Generex has agreed to sell an aggregate of 15.31 million shares of its common stock and warrants to purchase up to 5.05 million additional shares of its common stock.

[More...]

Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter

Tue, 20 Oct 2009 20:05:00 GMT

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement.
The share price increase followed Dendreon's positive Phase III prostate cancer immunotherapy results during March 2009.
Two companies have lead the CI Index during the quarter in both growth and potential growth.

[More...]

StockPreacher.Com Issues Trading Outlook for Novadel Pharma Inc.

Fri, 25 Sep 2009 11:52:00 GMT

DALLAS, Sept. 25, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring specialty drug maker Novadel Pharma Inc. (AMEX:NVD).
The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Novadel Pharma Inc. (AMEX:NVD) should be of particular interest to other drug delivery and formulation companies: Generex Biotechnology Corp. (Nasdaq:GNBT), CPEX Pharmaceuticals Inc. (Nasdaq:CPEX), Hospira Inc. (NYSE:HSP) and Acusphere Inc. (Pink Sheets:ACUS).

[More...]

Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead By ImmunoCellular Therapeutics

Wed, 16 Sep 2009 14:13:00 GMT

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting.
CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D. The increased interest in the immunotherapy companies and growth of the sector followed the positive Phase III results of Dendreon (NASDAQ:DNDN), a CI Index component company, for its prostate cancer product and resulting 1,000% share price improvement during the Spring of 2009.
In addition to ImmunoCellular Therapeutics and Dendreon, the CI Index features Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (PINK SHEETS:BVTI), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (NWBO.OB), CEL -- SCI Corp. (AMEX:CVM), Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express and Mentor Capital, Inc. (PINK SHEETS:MNTR) as proxy for its investee Quantum Immunologics, Inc.

[More...]

New Cancer Immunotherapy Index Posts 23% Gains Lead By Mentor Capital, Inc. And Oncothyreon

Fri, 28 Aug 2009 18:06:00 GMT

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009.
Dendreon (NASDAQ:DNDN), with $2.7 Billion market capitalization, is the largest company in the Cancer Immunotherapy Index, and experienced a 1,000% share price gain during the Spring of 2009.
In addition to Mentor Capital, Oncothyreon and Dendreon, the CI Index features ImmunoCellular Theraputics (IMUC.OB), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (NWBO.OB), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express.

[More...]

Generex Biotechnology Corporation's Synthetic Vaccine Platform Represented At International Swine Flu Conference

Thu, 27 Aug 2009 12:27:00 GMT

The synthetic vaccine platform technology of Generex Biotechnology Corporation was featured last week at the first International Swine Flu Conference in Washington, DC.[More...]

Generex Biotechnology CEO Anna Gluskin Featured On BNN News to Discuss Potential for H1N1 Vaccine

Mon, 24 Aug 2009 18:20:00 GMT

Anna E. Gluskin, the chairman, president and CEO of Generex Biotechnology Corporation , was featured this morning on 'Market News' on Canada's Business News Network to discuss the current circumstances of H1N1 and how Generex's synthetic vaccine platform can respond to the swine flu's ever-changing DNA. The segment can be viewed online at http://watch.bnn.ca/clip206593#clip206594 and will be available later today at www.generex.com.[More...]

Generex Announces Sales Agreement With McCarthy and Sons Service

Tue, 18 Aug 2009 12:26:00 GMT

Generex Biotechnology Corporation , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a sales agreement with McCarthy and Sons Service , a leading Canadian sales firm to veterinarians, pursuant to which McCarthy and Sons will promote sales of Glucose RapidSpray , the Company's proprietary glucose spray product, on an exclusive representation basis to veterinarian clinics and veterinarian hospitals in the animal health industry in Canada.[More...]

Generex Raises $5.65 Million in a Registered Direct Offering of Common Stock

Thu, 06 Aug 2009 20:49:00 GMT

WORCESTER, Mass., Aug. 6, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has today consummated a registered direct offering of 8,558,013 shares of its common stock to a select group of accredited investors at $0.6602 per share.
The offering resulted in gross proceeds of $5,650,000 and, after deducting placement agent's fees and estimated offering expenses, the Company received net proceeds of approximately $5,336,000.
Midtown Partners & Co., LLC served as placement agent for the offering.

[More...]

Generex Announces Publication of Pre-Clinical Studies Demonstrating Utility of Its Vaccine Platform for Addressing Pandemic Influenza

Wed, 05 Aug 2009 13:26:00 GMT

Generex Biotechnology Corporation today announced publication of pre-clinical studies conducted to identify vaccine peptides for the potentially pandemic H5N1 avian influenza virus. The report is the result of a collaboration between scientists at Antigen Express, Inc. , Generex's wholly-owned immunotherapeutics subsidiary, and Dr. John Treanor .[More...]

Amgen Co-Founder to Act As Generex Chief Scientific Advisor; Generex Engages Dr. Joseph Rubinfeld to Spearhead the Company's Scientific Development and Commercialization Plans for Its Drug Delivery Platform and Vaccine Technologies

Tue, 04 Aug 2009 14:45:00 GMT

WORCESTER, Mass., Aug. 4, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Dr. Joseph Rubinfeld, one of the original founders of Amgen, Inc., has agreed to act as the Company's Chief Scientific Advisor.
Dr. Rubinfeld will assist the Company in developing and implementing product commercialization roadmaps for its proprietary drug delivery platform and its synthetic vaccine platform technology programs.
In addition to his efforts in founding Amgen, Dr. Rubinfeld has a fifty year history in pharmaceutical and consumer product development.

[More...]

Form 4 GENEREX BIOTECHNOLOGY For: Oct 19 Filed by: Masterson Nola E (10K)

Mon, 19 Oct 2009 22:45:00 GMT

[More...]

Form 4 GENEREX BIOTECHNOLOGY For: Jan 12 Filed by: FLETCHER MARK (10K)

Mon, 12 Jan 2009 21:44:00 GMT

[More...]

Form 4 GENEREX BIOTECHNOLOGY For: Oct 31 Filed by: FLETCHER MARK (10K)

Mon, 03 Nov 2008 14:58:00 GMT

[More...]

Form 4 GENEREX BIOTECHNOLOGY For: May 27 Filed by: PERRI ROSE C (10K)

Thu, 29 May 2008 20:01:00 GMT

[More...]

Form 4 GENEREX BIOTECHNOLOGY For: May 27 Filed by: GLUSKIN ANNA E (10K)

Thu, 29 May 2008 20:01:00 GMT

[More...]